Close Menu

A Myth

PureTech Ventures' John LaMattina this week says "there has never really been 'low-hanging fruit' in pharma R&D." Writing in Forbes, the former president of R&D at Pfizer says "the fact of the matter is that drug discovery has always been hard and that there have been spectacular failures over the years in pursuit of what its retrospectively viewed as 'low-hanging fruit,'" or easily attainable targets. "For decades, the fruit has always been hard to reach.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.